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Neuropathology of Parkinson 
Disease





• In the case of Lewy body disease, α-
synuclein builds up within neurons, 
leading to cell death
• This protein especially aggregates 
within the basal ganglia, which leads to 
movement impairment
• These movement impairments are the 
reason Lewy body disease is closely 
linked with Parkinson’s disease
Parkinson’s Disease
• The definition of Parkinson’s disease is generally 
loose
• Parkinson’s Disease (PD) is diagnosed based on a 










• Build of α-synuclein protein in neurons
• Somatic deficits
Multiple System Atrophy
• Build up of α-synuclein in glial cells
• Autonomic deficits
Progressive Supranuclear Palsy
• Build up of tau protein
• Characteristic eye movements
Corticobasal Degeneration
• Build up of tau protein
• Limb problems
Basal Ganglia
• Facilitates motor movement
• Composed of five parts: (1) caudate, (2) putamen, (3) globus pallidus, 
(4) substantia nigra, and the (5) subthalamic nucleus
Denervation in substantia nigra & striatum
• Dopaminergic cells of the substantia nigra die because of an excess of 
calcium ions in the basal ganglia
• This calcium-induced cell death is accompanied by buildup of α-
synuclein proteins which kills cells as well
• Thus, the substantia nigra is severely disfigured in Lewy body disease 
patients
• The input device (striatum) is also dying, leading to poorer reception 
and communication → reduced motor movement
Postmortem characterization of PD patients
• The researcher investigated 132 patients diagnosed with Parkinson’s 
disorder and found that Lewy Body disease (build up of α-synuclein) 
was the cause in most of these patients
Misdiagnosis in neurodegenerative diseases
• “The diagnostic accuracy of pathologically confirmed MSA in the 
Mayo Clinic brain bank is less than that for PSP (about 70%).”
• “Cases with autopsy confirmed MSA are most often misdiagnosed 
clinically as either PSP (47%) or atypical PD (34%).”
• There seems to be a theme of misdiagnosis in neurodegenerative 
disorders.
• What are some potential issues that arise when misdiagnosing these 
disorders?
• What could we do to prevent misdiagnosis?
Postmortem studies
• The author believes that postmortem 
stories are the most accurate as 
scientists can confirm the development 
of protein aggregates in specific 
locations
• However, the same level of accuracy is 
not achieved in antemortem diagnosis 
and treatment
• Detection tools should be developed to 
better diagnose patients while they are 
living
Genes affecting PD development
• PD onset as the result of inheritance is 
uncommon (no clear genetic link)
• However, several proteins can play a role
• Dysfunctional α-synuclein protein
• LRRK2




Braak stages in PD development
• Stages 1-2: protein aggregates are largely 
within the medulla oblongata and the 
olfactory bulb (affecting autonomic 
functions and smell)
• Stages 3-4: Pathological changes in 
substantia nigra
• By now, the symptoms are evident
• Stages 5-6: Inclusions in the cerebral 
cortex
• Day to day life is severely affected 
Conclusion
• This survey of autopsies demonstrates the importance of analyzing 
postmortem brains to study neurodegenerative disease development
• Misdiagnosis of neurodegenerative disorders can be traced to the lack 
of accurate detection tools
• Analyzing autopsies can reveal the physiological differences in 
patients with PD (synucleinopathy vs. tauopathy)
Discussion Questions
• Many of the problems involving the differences in neurodegenerative 
diseases lie in the general definitions. Should we try to diffuse the 
idea of Parkinson’s disease and promote more specific pictures like 
Lewy body buildup or tau protein buildup (as in Alzheimer’s disease)?
• What is the causing the difficulty in diagnosing these diseases as the 
patients are alive? Should doctors use more invasive methods (e.g. 
biopsy) to diagnose disease?
• Many of the current treatments for neurodegenerative diseases are 
not disease-modifying. They attack the symptoms instead. How can 
we produce disease-modifying treatments?
Discussion Questions
• There is a wide variety 
of diseases causing PD. 
How would this hinder 
or help the awareness 
and treatment of this 
disease?
• Should we switch to osteopathic forms of medicine rather than 
allopathic forms of medicine for patients that do not have genetically-
linked disorders? That is, should doctors put a greater emphasis on 
lifestyle changes rather than the medicines they prescribe for patients?
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